AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 10:05:06 16/01/2026 pm IST			5-day change	1st Jan Change
14,052.00 ^GBX	+0.19%		-1.15%	+1.90%

16/01	ASTRAZENECA : Buy rating from UBS	ZD
16/01	ASTRAZENECA : Deutsche Bank gives a Sell rating	ZD

AstraZeneca benefits from oncology momentum but valuation limits upside

AstraZeneca's strong growth in oncology, rare diseases, respiratory and cardiovascular therapies supports upgraded long-term assumptions and a higher target price. Yet, after a sharp year-to-date share price rally, its premium valuation already reflects much of the improved growth outlook.

Published on 11/19/2025 at 06:13 pm IST

Alphavalue

AstraZeneca benefits from oncology momentum but valuation limits upside

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about AstraZeneca PLC

16/01	ASTRAZENECA : Buy rating from UBS	ZD
16/01	ASTRAZENECA : Deutsche Bank gives a Sell rating	ZD
16/01	BofA cuts British Land; RBC raises Gym Group	AN
15/01	N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading -- Update	DJ
15/01	Emergent BioSolutions' Former CEO Sued for Insider Trading by New York Attorney General	MT
15/01	N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading	DJ
15/01	Stocks in green as US manufacturing surprises	AN
15/01	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
15/01	European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading	MT
15/01	AstraZeneca, Abu Dhabi Biobank to Advance Precision Medicine, New Healthcare Practices	MT
15/01	ASTRAZENECA : Barclays reiterates its Buy rating	ZD
15/01	ASTRAZENECA : Gets a Buy rating from JP Morgan	ZD
15/01	Swedish Stocks in North America - Ericsson Down 0.7 Percent	FW
15/01	Sector Update: Health Care Stocks Higher Late Afternoon	MT
15/01	Sector Update: Health Care Stocks Advance in Afternoon Trading	MT
14/01	Sanofi CEO says expects flu-COVID combo vaccines in 2027-2028 to drive next surge in vaccine uptake	RE
14/01	London's FTSE 100 notches new high on mining, healthcare boost	RE
14/01	European Stocks Close Mixed in Wednesday Trading; Rising UK Business Growth 'Good Omen'	MT
14/01	Bonesupport Surges on Preliminary Figures, OMXS30 Index Closes Flat	FW
14/01	US, European regulators set principles for 'good AI practice' in drug development	RE
14/01	Sector Update: Health Care Stocks Mixed Premarket Wednesday	MT
14/01	Sector Update: Health Care	MT
14/01	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Ahead of Expected Supreme Court Decision on Tariffs	MT
14/01	Hutchmed China hails lung cancer trial results published in Lancet	AN
14/01	Miners lift FTSE 100 ahead of US PPI	AN

Chart AstraZeneca PLC

Duration

Period

AZN: Dynamic Chart

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

10/02 - Q4 2025 Earnings Release

More about the company